On March 15, 2023 Aptamer Science reported the company that it will participate in the American Association for Cancer Research (AACR) (Free AACR Whitepaper) and present research results on ‘CD25-ApDC immunotherapy’ (Press release, Aptamer Sciences, MAR 15, 2023, View Source;idx=234 [SID1234641617]). The presentation abstracts selected this time will be released on the AACR (Free AACR Whitepaper) official website on the 31st.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AACR is the world’s largest international cancer society where more than 20,000 researchers from over 120 countries gather every year to share cancer-related knowledge and clinical research.

This year, it will be held in Orlando, Florida, USA from April 14th to 19th (local time).

Aptamer Science plans to present research results on the topic of ‘Removal and inhibition of regulatory T cells by aptamer-drug transporter targeting human CD25’.

‘CD25-ApDC immune anti-cancer drug’ specifically binds to CD25 on regulatory T cells within tumors to prevent cancer cells from evading the body’s immune system.

In particular, CD25-ApDC not only selectively suppresses the function of Treg cells, but also promotes immune function by inducing the activation of cytotoxic T cells and antigen-labeling cells that prevent tumor growth.

The study on ‘CD25-ApDC immune anti-cancer drug’ presented at this conference has been selected for the National New Drug Development Industry hosted by the Korea New Drug Development Foundation (KDDF), and mechanism research and animal model evaluation are currently in progress at the lead material stage.

Lee Dae-gyeon, head of Aptamer Science Research and Development Division, said, "I believe that the presentation at this global conference will be an opportunity to verify the feasibility and competitiveness of aptamer-based immunotherapy research."

"Based on this, we plan to secure momentum for developing treatments and speed up development to conclude early partnerships in the future."

Go to article: Aptamer Science announces immunotherapy research results at AACR (Free AACR Whitepaper) in the U.S.